Combination Chemotherapy of L1210 Leukemia With Platinum Compounds and Cyclophosphamide Plus Other Selected Antineoplastic Agents 2

Abstract

Six antitumor platinum compounds were used in combination with cyclophosphamide plus 1 of 7 other antitumor drugs for treatment of L1210 leukemia in B6D2F1 [(C57BL/6 × DBA/2) F₁] mice. Data obtained from each three-agent regimen were compared with those obtained after administration of each compound alone and each appropriate two-agent combination. No cure (>60-day survival) was obtained with any compound used alone. Combination of cyclophosphamide with a platinum compound (Pt+CY) yielded a collective cure rate of 193/420, and the addition of a third drug to the Pt+CY combination increased by 50% the collective cure rate to 290/420 (P<0.001). Certain regimens produced 100% cure rates. The most effective drugs when used in combination with PT+CY were cytosine arabinoside, 5-fluorouracil, hydroxyurea, and Yoshi-864. Adriamycin, methotrexate, and vincristine were less effective at the doses used. Toxicity, as evidenced by maximum weight loss, was slightly greater with the three-agent combinations than with the Pt+CY regimens